GlassScriptPhysician profile
Earle U Scharff
NPI 1982637153
$3,876.86
in general payments reported to CMS, 2019-2025
18 companies · $1,376 in 2025
The $1,376 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $359 · 2021: $412 · 2022: $233 · 2023: $729 · 2024: $306 · 2025: $1,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,405.59 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $580.09 | 2023-2025 | Miebo, Xiidra, Alden Scleral Zenlens |
| Johnson & Johnson Vision Care, INC. | $437.47 | 2019-2025 | Acuvue, Acuvue Revitalens Mpds |
| Alcon Vision LLC | $421.92 | 2022-2025 | Tryptyr, Rhopressa, Simbrinza |
| Sun Pharmaceutical Industries INC. | $337.59 | 2019-2025 | Cequa |
| Coopervision INC. | $294.59 | 2022-2025 | Misight Contact Lens, Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $279.73 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $271.75 | 2019-2020 | |
| Dompe US, INC. | $215.08 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $200.84 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $168.28 | 2024-2025 | Xdemvy |
| Allergan, INC. | $135.34 | 2019-2021 | |
| Sight Sciences, INC. | $122.67 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ocular Therapeutix, INC. | $117.65 | 2023 | Dextenza |
| Glaukos Corporation | $92.99 | 2025 | |
| Biotissue Holdings INC. | $76.59 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $56.14 | 2022-2025 | Ozurdex |
| Kala Pharmaceuticals, INC. | $51.46 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $16.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earle Scharff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.